Health Catalyst’s Q3 CY2025: Revenue Beats Expectations, But Sales Guidance Falls Short

Health Catalyst (NASDAQ:HCAT) has released its financial results for the third quarter of 2025, and while revenue exceeded analysts’ expectations, sales guidance for the next quarter fell below estimates.

Revenue Growth at a Glance

Health Catalyst’s total revenue for Q3 CY2025 was $76.32 million, beating Wall Street’s estimate of $75.01 million by 1.7%. This performance marks a flat year-on-year revenue growth for the company. However, when looking ahead, Health Catalyst is guiding for a 7.7% year-over-year decline in sales for next quarter.

Revenue Guidance

The company’s management has provided guidance for Q4 CY2025, with a midpoint of $73.5 million at analysts’ estimates. This number falls below the projected $74.81 million estimated by analysts. Additionally, Health Catalyst is projecting an EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) margin of 15.7% for Q3 CY2025, exceeding analysts’ expectations.

Operating Margin and Free Cash Flow

Health Catalyst’s operating margin decreased from -17.9% in the same quarter last year to -22.9%. This dip is accompanied by a decrease in free cash flow, which was -$5.27 million compared to -$14.19 million in the previous quarter.

Market Capitalization and CEO Comments

The company’s market capitalization stands at $199.2 million. Dan Burton, CEO of Health Catalyst, commented on the third quarter’s financial results: "I am pleased by our financial results, including total revenue of $76.3 million and Adjusted EBITDA of $12.0 million, with these results beating our quarterly guidance on each measure."

Company Overview

Health Catalyst is built around its "Health Catalyst Flywheel" methodology, which emphasizes measurable outcomes. The company provides data and analytics technology and services to healthcare organizations, helping them manage their data and drive improvements.

Revenue Growth Analysis

A company’s long-term sales performance can serve as a signal of its overall quality. Health Catalyst has experienced annual revenue growth at 12% over the last five years but fell short of our standards for the software sector, which enjoys several secular tailwinds. This quarter’s flat year-on-year growth and next quarter’s guided decline indicate that demand may be slowing.

Health Catalyst’s Recent Performance

Looking ahead to future quarters, analysts expect a deceleration in revenue growth for Health Catalyst. The company is guiding for a 7.7% year-over-year decline in sales for Q4 CY2025. This projection suggests its products and services are experiencing some demand headwinds. Sell-side analysts have projected a moderate decline of 3.9% over the next 12 months, a signal that Health Catalyst is likely to face ongoing competition.

Customer Acquisition Efficiency

Health Catalyst’s recent customer acquisition efforts suffered from high inefficiency, leading to a negative customer acquisition cost (CAC) payback period this quarter. This represents a situation in which its incremental sales and marketing investments outpaced revenue. Such an efficiency indicates operation in a highly competitive environment where products may lack significant differentiation.

Key Takeaways

Health Catalyst exceeded analysts’ EBITDA expectations in Q3 CY2025, with $12 million against estimates of $10.39 million. However, next quarter’s EBITDA guidance fell short, indicating the company might not be able to maintain its competitive edge.

Should You Invest in Health Catalyst?

Considering the above analysis, it becomes clear that while the stock presents some positive signs, such as beating analysts’ expectations on several key metrics, there are also warning signals. The negative customer acquisition cost payback period and the decline in sales guidance imply ongoing challenges for growth. For a comprehensive understanding of Health Catalyst’s business quality, including its products, market performance, and competitive position, we recommend reading our full research report.

Conclusion

Health Catalyst’s Q3 CY2025 results show both positive and concerning trends. The company has continued to grow revenue significantly, but its customer acquisition cost efficiency remains a concern. Its projected decline in sales for the next quarter could have negative implications on long-term growth prospects. Further analysis is needed to determine whether Health Catalyst presents an attractive investment opportunity at its current price.